ReDC1 cell lines and technology services for APC-dependent discovery and translation
CrossRelay offers research-use-only ReDC1 dendritic cell lines and technology services for teams working on antigen presentation, immune assay development, CTL-oriented studies, and translational immunology workflows.
The product and service offering is built around a scalable cDC1-like APC foundation. For scientific teams, the value lies in a more defined APC context; for translational and strategic partners, the value lies in a platform that can support repeatable product supply, technical services, and future platform expansion.
A product portfolio and service capability built around a scalable APC platform
Research-use-only ReDC1 cell lines
Available products are presented as ReDC1 lines derived from healthy-donor peripheral blood and maintained as mature activated dendritic-cell lines suitable for APC-centered research workflows.
The currently listed portfolio includes HLA-defined lines such as MD54, MD48, and MD74, providing a practical entry point for APC-dependent study design.
Generation and validation services
The service offering is organized around three pillars: custom generation of dendritic cell lines, extensive phenotypic and functional characterization, and comprehensive validation for immunological applications.
Together, these services position CrossRelay not only as a product supplier, but as a technical platform partner for APC-dependent scientific programs.
Available ReDC1 cell lines for research use
MD54
MD48
MD74
The listed ReDC1 lines originate from healthy-donor peripheral blood mononuclear cell sources and are positioned for research use in APC-dependent studies.
The lines are positioned as mature activated dendritic-cell products relevant to naïve T-cell priming and antigen-specific T-cell responses.
The broader product direction also includes related research components such as tumor antigens, HLA molecules, and DC-related molecules.
Technology services for custom line generation, characterization, and validation
Custom generation of dendritic cell lines
CrossRelay offers custom generation of human dendritic cell lines based on client-specific phenotype, functional, and scalability requirements.
Customization can include stable line generation and selected genetic modifications intended to support antigen-presentation, immune-modulation, and pathway-specific research programs.
Extensive phenotypic and functional characterization
Characterization services include surface-marker validation, stability testing, antigen-uptake and processing assays, and cytokine profiling to assess immune-modulatory function.
Markers listed in the service deck include HLA-DR, CD11c, CD205, CD80, CD83, and CCR7.
Comprehensive immunological validation
Validation services include T-cell activation assays, mixed lymphocyte reaction assays, and vaccine-related functionality testing focused on antigen presentation and CTL stimulation.
The service scope also includes support for αβ and γδ T-cell applications together with comprehensive functional reporting.
Why CrossRelay and ReDC1 are positioned differently from conventional DC workflows
The lines are presented as already established mature activated dendritic-cell lines, reducing reliance on long differentiation protocols used in conventional MoDC or stem-cell-derived workflows.
Because the lines are immortalized and standardized, they are positioned as a scalable supply solution with lower batch-to-batch variability than donor-limited primary-cell methods.
The platform also benefits from the practicality of genetic engineering on stable cell lines for APC enhancement, immune-modulation studies, and reproducible platform development.
Master cell banks, defined specifications, and reduced donor-dependent variability support standardization, reproducibility, and a clearer translational manufacturing logic.
Repeated functional testing is an advantage of line-based APC systems, particularly for profiling antigen presentation and T-cell activation stability over multiple passages.
CrossRelay is differentiated from MoDCs, HSC-DCs, iPSC-DCs, leukemic DC-like lines, and direct-reprogramming approaches by emphasizing mature phenotype, operational simplicity, and scalable consistency.
Cell-line licensing process
Contact CrossRelay
Begin with an inquiry describing the cell line or service need, study context, and desired HLA or APC-related requirements.
Review licensing terms
Review and sign the relevant licensing term sheet or transfer documents for research-use-only access.
Complete documentation and payment
Finalize the required documentation, complete the commercial terms, and confirm shipment readiness.
Receive cell lines
Receive the selected ReDC1 cell line product and supporting information for downstream research workflows.